moxidectin / Generic mfg. - LARVOL DELTA

Resistance to ivermectin, doramectin and moxidectin in Rhipicephalus microplus isolates from Rio Grande do Sul, Brazil. (PubMed, Vet Parasitol Reg Stud Reports) - "This is the first study to demonstrate side-resistance among drugs of the macrocyclic lactones family of anti-parasitic drugs in R. microplus from south Brazil. The results obtained reinforce the importance of acaricide resistance detection with laboratory bioassays and have an impact on cattle tick control strategies, since side-resistance among the macrocyclic lactones limits the availability of drugs to be used."

Journal

Efficacy evaluation of a new oral chewable tablet containing fluralaner, moxidectin, and pyrantel (BRAVECTO® TriUNO) against hookworm and Toxascaris leonina infections in a non-terminal study design in dogs. (PubMed, Parasit Vectors) - "A single, orally administered dose of this chewable tablet formulation is effective in treating canine infections with adult hookworms (U. stenocephala, A. caninum) and T. leonina. Non-terminal studies present a valid means of determining the efficacy of anthelmintic treatments for these canine intestinal parasites."

Journal • Infectious Disease

The Death to Onchocerciasis and Lymphatic Filariasis (DOLF) project: Accomplishments and ongoing research. (PubMed, PLoS Negl Trop Dis) - "More recently, we have shown that single-dose treatment with moxidectin plus albendazole is superior to the ivermectin plus albendazole regimen currently recommended for LF elimination in Africa. DOLF has also addressed the issue of MDA compliance, because improved treatments cannot be effective if people do not swallow the tablets. We highlight here some of DOLF's important discoveries that support the control and elimination of neglected tropical diseases caused by helminths."

Journal • Review • Infectious Disease • Ophthalmology

Mechanistic insights into ammonium-driven metabolic regulation for enhanced nemadectin biosynthesis in Streptomyces cyaneogriseus. (PubMed, Bioresour Bioprocess) - "Its derivative moxidectin, featuring a C-23 methoxime modification, demonstrates enhanced insecticidal activity and has become a commercially successful agrochemical...Metabolomic dynamics revealed reinforced precursor biosynthesis through coordinated metabolic reprogramming: enhanced acetyl-CoA production, reinforced Embden-Meyerhof-Parnas pathway and amino acid/acyl-CoA metabolism, coupled with reduced tricarboxylic acid cycle activity. Systematic integration of physiological phenotyping, metabolite profiling, and transcriptional regulation data comprehensively elucidated the ammonium-driven overproduction mechanism, providing critical insights for developing advanced fermentation strategies and genetic engineering approaches in industrial antibiotic production."

Journal • AVEN

Moxidectin for LF, Cote d'Ivoire (DOLF) (clinicaltrials.gov) - P3 | N=164 | Completed | Sponsor: Washington University School of Medicine | Active, not recruiting ➔ Completed

Trial completion

Resistance to triclabendazole in Fasciola hepatica on a commercial sheep farm in Taranaki, New Zealand. (PubMed, N Z Vet J) - "Ewes were either left untreated as controls or treated with a single oral dose of either a combination of 0.2 mg/kg moxidectin and 10 mg/kg triclabendazole or 10 mg/kg triclabendazole alone, both at the manufacturer's recommended dose...The finding of triclabendazole-resistant liver fluke in New Zealand should alert farmers and veterinarians to consider triclabendazole resistance as a potential cause of treatment failure, and adapt the farm liver fluke management and treatment regimens. In addition, resistant fluke could be widespread around New Zealand due to livestock being sold from this farm."

Journal

Topically administered macrocyclic lactone products, including eprinomectin, demonstrate comparable neurological safety in cats based on pharmacovigilance data. (PubMed, J Am Vet Med Assoc) - "The openFDA and EudraVigilance Veterinary Data Warehouse databases were queried for neurological AEs cumulatively reported through December 31, 2024, for marketed parasiticide products containing MLs (eprinomectin, selamectin, moxidectin) and emodepside for topical administration to cats. An evaluation of pharmacovigilance data from 2 different sources revealed no evidence of greater proportional reporting for neurological AEs specific to the use of eprinomectin-containing products in cats than for other MLs or emodepside. These findings supported the conclusion that ML-containing products (including eprinomectin-containing products) and emodepside are comparable in the frequencies and types of neurological AEs associated with feline topical parasiticide products described as substrates for P-glycoprotein transporters."

Adverse events • Journal • Ataxia • CNS Disorders • Epilepsy • Movement Disorders

Field efficacy assessment of a combination of afoxolaner, moxidectin and pyrantel pamoate to treat dogs naturally infested with Sarcoptes scabiei. (PubMed, Parasite) - "Treated dogs had no pruritus, papules or crusts and clear evidence of hair regrowth by Day 56, unlike the dogs in the control group. This study demonstrated the elimination of S. scabiei mites and significant improvement of sarcoptic mange clinical signs in naturally infested dogs treated with the oral combination of afoxolaner, moxidectin and pyrantel."

Clinical • Journal • Dermatology • Pruritus

Blood bronchial mucus with an adult Dirofilaria immitis worms after the treatment with doxycycline and moxidectin. a rare case presentation. (PubMed, Parasitology) - No abstract available

Journal

Independent impacts of co-formulants contained in anthelmintic formulations on seed germination of grassland species. (PubMed, Environ Res) - "The seeds of four species of temperate grasslands (Achillea ptarmica, Agrostis capillaris, Dianthus deltoides, Plantago lanceolata) were exposed to a commercial moxidectin formulation at a concentration of 10 mg l-1 as well as three of its co-formulants: benzyl alcohol (BA), butylated hydroxytoluene (BHT) and disodium ethylenediamine tetraacetic acid (EDTA-Na2)...The strong effects of BA and BHT on seed germination suggest that their contribution to effects of anthelmintic formulations is at least partly due to an independent impact. Therefore, co-formulants should be given greater consideration both in the design of ecotoxicological experiments and in environmental risk assessments."

Journal • Addiction (Opioid and Alcohol)

Efficacy of sarolaner in Simparica® (sarolaner) chewables and Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) against two US strains of Haemaphysalis longicornis. (PubMed, Parasit Vectors) - "Results from these controlled studies demonstrated high efficacy (78.4-100%) of Simparica and Simparica Trio in reducing existing and subsequent infestations of H. longicornis within 48 h for up to 65 days post treatment."

Journal

Functional Characterization of the Cat and Dog Wild-Type and Mutant MDR1 Carrier Proteins and Frequency of the MDR1 Gene Mutation in 800 Cats From Germany. (PubMed, J Vet Pharmacol Ther) - "In both cell lines, significant MDR1-mediated rhodamine 123 efflux was identified for the wild-type MDR1 proteins, but not for the mutant MDR1 proteins, confirming a complete loss-of-function phenotype due to MDR1 gene mutation. Competitive in vitro studies showed inhibition of both wild-type MDR1 carriers with the reference MDR1 inhibitors verapamil (IC50 = 5-9 μM), PSC833 (IC50 = 1-2 μM), and tariquidar (IC50 = 0.1-0.2 μM), as well as with the antiparasitic drugs ivermectin (IC50 = 3-4 μM), eprinomectin (IC50 = 3-4 μM), moxidectin (IC50 = 8-21 μM), selamectin (IC50 = 10-22 μM), lotilaner (IC50 = 11-23 μM), and sarolaner (IC50 = 30-57 μM), clearly demonstrating multi-drug interactions with the MDR1 carriers from both species."

Journal • ABCB1

Integrated pharmacokinetic-pharmacodynamic analysis of macrocyclic lactones in sheep infested with resistant Psoroptes ovis. (PubMed, Vet Parasitol) - "The current study aimed to investigate the pharmacokinetic/pharmacodynamic (PK/PD) relationship of five macrocyclic lactone (MLs) formulations, three 1 % formulations (ivermectin, doramectin and moxidectin) and two long-acting 3.15 % products (ivermectin and doramectin), against sheep experimentally infested with resistant Psoroptes ovis under standardized doses...The Cmax/MIC ratio observed for 1 % formulations were significantly higher compared to those obtained with the long-acting formulations at both MIC levels. For the AUC/MIC parameter, the 1 % formulations exhibited significantly higher values compared to the long-acting formulations for the MIC 30 ng/mL.These findings suggest that both the magnitude and duration of MLs in plasma are critical for efficacy against P. ovis."

Journal • PK/PD data

Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis (clinicaltrials.gov) - P3 | N=323 | Active, not recruiting | Sponsor: Medicines Development for Global Health | Trial completion date: Jul 2026 ➔ Jan 2026

Trial completion date • Infectious Disease

Activity of antifilarial drugs on microfilaremia in the treatment of loiasis: a systematic review. (PubMed, Parasit Vectors) - "Antifilarial drug efficacy against L. loa microfilaremia varies by dosage and treatment duration, with IVM and DEC demonstrating rapid, high efficacy but presenting safety concerns for hypermicrofilaremic individuals. ALB and MBZ show efficacy with extended treatment but are slower acting. Further research is needed to optimize treatment regimens and assess clinical outcomes beyond microfilaremia reduction."

Journal • Review

Efficacy of oral afoxolaner and a combination of afoxolaner, moxidectin, and pyrantel against Amblyomma maculatum in dogs. (PubMed, Parasit Vectors) - "The results of these studies demonstrate that NexGard® and NexGard® Plus administered once at or near the minimum recommended dose of 2.5 mg/kg afoxolaner is effective for the treatment of existing A. maculatum infestations and for the control of infestations through Day 31."

Journal • Infectious Disease

Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis (clinicaltrials.gov) - P2 | N=300 | Active, not recruiting | Sponsor: Washington University School of Medicine | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Infectious Disease

Long-term safety of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), a novel orally administered combination endectocide for dogs. (PubMed, Parasit Vectors) - "This study demonstrates that Credelio Quattro exhibits a wide safety margin when administered monthly to puppies and dogs at the maximum recommended commercial dose, with only transient gastrointestinal symptoms similar to other oral antiparasitic products observed. Therefore, Credelio Quattro may be safely administered to dogs each month in accordance with the approved label."

Journal • Hematological Disorders

Efficacy of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) chewable tablets in the prevention of Borrelia burgdorferi transmission from infected Ixodes scapularis in dogs. (PubMed, Parasit Vectors) - "The laboratory studies described herein confirm that a single dose of lotilaner, at the minimum effective dosage of 20 mg/kg, administered as Credelio Quattro, in combination with moxidectin, praziquantel, and pyrantel or Credelio, is effective for the prevention of transmission of B. burgdorferi from infected I. scapularis for a full month in dogs."

Journal • Infectious Disease • Inflammatory Arthritis • Lyme Disease

Identification of potential mediators of moxidectin-induced developmental toxicity using network toxicology and structure-based analyses. (PubMed, Ecotoxicology) - No abstract available

Journal

Simparica Trio® kills Ctenocephalides felis on dogs and provides month-long protection against the transmission of Dipylidium caninum. (PubMed, Parasit Vectors) - "The efficacy provided by Simparica Trio against C. felis at the minimum dosage of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin, and 5 mg/kg pyrantel (as pamoate salt) prevented D. caninum infection in dogs for 1 month."

Journal • Gastrointestinal Disorder • Infectious Disease

Safety and efficacy assessment of a chewable tablet containing sarolaner, moxidectin, and pyrantel in the treatment of Angiostrongylus vasorum in dogs. (PubMed, Vet Parasitol) - "Compared to the pre-treatment faecal larvae counts a geometric mean percent reduction of 96.7 % was observed on Day 30 and 99.1 % on Day 60 in the SMP treated group. Both in the experimental and in the field study, SMP as a chewable tablet was well tolerated and resulted in a high efficacy against adult A. vasorum infections after a single treatment."

Journal • Infectious Disease

Progress towards enabling access to moxidectin for onchocerciasis elimination programme (ASTMH 2025) - No abstract available

Infectious Disease

Using the new guideline for diagnosing anthelmintic resistance of gastrointestinal nematodes to different chemical components in sheep in the Rio Grande do Norte State, Brazil. (PubMed, Rev Bras Parasitol Vet) - "The faecal egg count reduction test (FECRT) was carried out to evaluate the pre- and post-treatment of anthelmintics, including albendazole, closantel, disophenol, ivermectin, levamisole, monepantel, moxidectin and trichlorfon, using the new classification criteria to analyze the results of an FECRT, which defined three possible classifications: susceptible, resistant and inconclusive...Two drugs (trichlorfon and monepantel) proved to be highly effective in treating gastrointestinal nematodes, presenting CI varying from 98 to 100% and 97 to 100%, respectively. Gastrointestinal nematodes from sheep raised in the in the Rio Grande do Norte State, Brazil are susceptible to the active principles trichlorfon and monepantel."

Journal

P-glycoprotein-9-mediated multidrug tolerance in Caenorhabditis elegans. (PubMed, Parasit Vectors) - "These results provide the first direct evidence that PGP-9 is necessary for multidrug tolerance in C. elegans, independently of amphid structural defects and NHR-8 regulation. These findings uncover a novel mechanism supporting drug resistance and highlight PGP-9 as a potential therapeutic target to improve ML treatments."

Journal